News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Radius (RDUS) To Announce Second Quarter 2014 Financial Results, Host Conference Call And Live Webcast On Aug 12, 2014


8/6/2014 9:15:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter 2014 financial results on Tuesday, August 12, 2014.

In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8.30 a.m. ET on Tuesday, August 12, 2014 to discuss the results.

Conference Call Information:

Date: Tuesday, August 12, 2014

Time: 8.30 a.m. ET

Domestic Dial-in Number: 1-201-493-6725

International Dial-in Number: 1-877-705-6003

Live webcast: http://public.viavid.com/index.php?id=110542

For those unable to participate in the conference call or webcast, a replay will be available beginning August 12, 2014 at 11:30 a.m. ET until September 12, 2014 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay passcode is 13588795.

A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 30 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. The company's lead development candidate is abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an abaloparatide transdermal patch for osteoporosis and RAD1901 for estrogen-driven breast cancer brain metastases. www.radiuspharm.com

CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.com Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Radius
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES